Dogwood Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
DWTX
- Investments
-
2
- Share Price
-
$1.05
- (As of Monday Closing)
Dogwood Therapeutics General Information
Description
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Contact Information
Website
www.dwtx.comCorporate Office
- 44 Milton Avenue
- Alpharetta, GA 30009
- United States
Corporate Office
- 44 Milton Avenue
- Alpharetta, GA 30009
- United States
Dogwood Therapeutics Timeline
Dogwood Therapeutics Stock Performance
As of 16-Nov-2026, Dogwood Therapeutics’s stock price is $1.05. Its current market cap is $40.5M with 38.2M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.05 | $1.11 | $0.90 - $7.04 | $40.5M | 38.2M | 85.4K | -$0.89 |
Dogwood Therapeutics Financials Summary
As of 30-Sep-2026, Dogwood Therapeutics has a trailing 12-month revenue of $100K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 36,407 | 224,173 | 1,277 | 6,287 |
| Revenue | 100 | 0 | 0 | 0 |
| EBITDA | (27,866) | (34,131) | (12,246) | (5,447) |
| Net Income | (25,180) | (34,257) | (12,350) | (5,296) |
| Total Assets | 75,608 | 90,171 | 94,308 | 4,165 |
| Total Debt | 118 | 163 | 15,586 | 0 |
Dogwood Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dogwood Therapeutics Comparisons
Industry
Financing
Details
Dogwood Therapeutics Competitors (6)
One of Dogwood Therapeutics’s 6 competitors is Tonix Pharmaceuticals Holding, a Corporation company based in Chatham, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding | Corporation | Chatham, NJ | ||||
| LeonaBio | Formerly VC-backed | Bothell, WA | ||||
| Jasper Therapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Kezar Life Sciences | Formerly VC-backed | South San Francisco, CA | ||||
| Paradigm Biopharmaceuticals | Corporation | Melbourne, Australia |
Dogwood Therapeutics Patents
Dogwood Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023341167-A1 | Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 | Pending | 16-Sep-2022 | ||
| EP-4587120-A2 | Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 | Pending | 16-Sep-2022 | ||
| WO-2024059247-A2 | Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 | Inactive | 16-Sep-2022 | ||
| WO-2024059247-A3 | Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 | Inactive | 16-Sep-2022 | ||
| US-20130203781-A1 | Aciclovir and celecoxib combination therapy for functional somatic syndromes | Inactive | 06-Feb-2012 | A61K31/196 |
Dogwood Therapeutics Signals
Dogwood Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dogwood Therapeutics Acquisitions (2)
Dogwood Therapeutics’s most recent deal was a Merger/Acquisition with Pharmagesic (Holdings) for . The deal was made on 07-Oct-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pharmagesic (Holdings) | 07-Oct-2024 | Merger/Acquisition | Drug Discovery | ||
| WEX Pharmaceuticals | 07-Oct-2024 | Merger/Acquisition | Drug Discovery |
Dogwood Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Dogwood Therapeutics FAQs
-
When was Dogwood Therapeutics founded?
Dogwood Therapeutics was founded in 2012.
-
Where is Dogwood Therapeutics headquartered?
Dogwood Therapeutics is headquartered in Alpharetta, GA.
-
What is the size of Dogwood Therapeutics?
Dogwood Therapeutics has 8 total employees.
-
What industry is Dogwood Therapeutics in?
Dogwood Therapeutics’s primary industry is Drug Discovery.
-
Is Dogwood Therapeutics a private or public company?
Dogwood Therapeutics is a Public company.
-
What is Dogwood Therapeutics’s stock symbol?
The ticker symbol for Dogwood Therapeutics is DWTX.
-
What is the current stock price of Dogwood Therapeutics?
As of 16-Nov-2026 the stock price of Dogwood Therapeutics is $1.05.
-
What is the current market cap of Dogwood Therapeutics?
The current market capitalization of Dogwood Therapeutics is $40.5M.
-
What is Dogwood Therapeutics’s current revenue?
The trailing twelve month revenue for Dogwood Therapeutics is $100K.
-
Who are Dogwood Therapeutics’s competitors?
Tonix Pharmaceuticals Holding, LeonaBio, Jasper Therapeutics, Kezar Life Sciences, and Paradigm Biopharmaceuticals are some of the 6 competitors of Dogwood Therapeutics.
-
What is Dogwood Therapeutics’s annual earnings per share (EPS)?
Dogwood Therapeutics’s EPS for 12 months was -$0.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process